MMP-9, a potential target for cerebral ischemic treatment

Current Neuropharmacology

Volumn 7, Issue 4, 2009, Pages 269-275

  Dong, Xue ^a   Song, Yu Ning ^a   Liu, Wei Guo ^a,b   Guo, Xiu Li ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia; Matrix metalloproteinase 9 (MMP 9); Regulation; Therapeutical target

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; BATIMASTAT; CALPAIN; CROCIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ESTROGEN; GELATINASE A; GELATINASE B; INDOMETACIN; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PLACEBO; PLASMINOGEN ACTIVATOR; PROSTAGLANDIN SYNTHASE INHIBITOR; QUERCETIN; RAMIPRIL; RESVERATROL; TETRACYCLINE DERIVATIVE; TRANDOLAPRIL; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; BLEEDING DISORDER; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

EID: 73649148680     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015909790031157     Document Type: Review

References (76)

1. Asahi, M., Asahi, K., Jung, J.C., del Zoppo, G.J., Fini, M.E., Lo, E.H. (2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab., 20, 1681-1689.
2. Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.C., Moskowitz, M.A., Fini, M.E., Lo, E.H. (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci., 21, 7724-7732.
3. Burggraf, D., Trinkl, A., Dichgans, M., Hamann, G.F. (2007) Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol. Dis., 25, 506-513.
4. Busti, C., Falcinelli, E., Momi, S., Gresele, P. (2009) Matrix metalloproteinases and peripheral arterial disease. Intern. Emerg Med., 2009 Sep 24, [Epub ahead of print].
5. Candelario-Jalil, E., Yang, Y., Rosenberg, G.A. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience, 158, 983-994.
6. Candelario-Jalil, E. (2008) Nimesulide as a promising neuroprotectant in brain ischemia: New experimental evidences. Pharmacol. Res., 57, 266-273.
7. Candelario-Jalil, E., Taheri, S., Yang, Y., Sood, R., Grossetete, M., Estrada, E.Y., Fiebich, B.L., Rosenberg, G.A. (2007) Cyclooxy genase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J. Pharmacol. Exp. Ther., 323, 488-498.
8. Castellanos, M., Leira, R., Serena, J., Pumar, J.M., Lizasoain, I., Castillo, J., Dávalos, A. (2003) Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke, 34, 40-46.
9. Chakraborti, S., Mandal, M., Das, S., Mandal, A., Chakraborti, T. (2003) Regulation of matrix metalloproteinases: An overview. Mol. Cell. Biochem., 253, 269-285.
10. Cho, J.Y., Kim, I.S., Jang, Y.H., Kim, A.R., Lee, S.R. (2006) Protective effect of quercetin, a natural flavonoid against neuronal damage after transient global cerebral ischemia. Neurosci. Lett., 404, 330-335.
11. Copin, J.C., Merlani, P., Sugawara, T., Chan, P.H., Gasche, Y. (2008) Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp. Neurol., 213, 196-201.
12. Coussens, L.M., Tinkle, C.L., Hanahan, D., Werb, Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103, 481-490.
13. Dzwonek, J., Rylski, M., Kaczmarek, L. (2004) Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS. Lett., 567, 129-135.
14. Ellerbroek, S.M., Halbleib, J.M., Benavidez, M., Warmka, J.K., Wattenberg, E.V., Stack, M.S., Hudson, L.G. (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res., 61, 1855-1861.
15. Fingleton, B. (2007) Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des., 13, 333-346.
16. Föerster, C., Kahles, T., Kietz, S., Drenckhahn, D. (2007) Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J. Physiol., 580, 937-949.
17. Gao, D., Zhang, X., Jiang, X., Peng, Y., Huang, W., Cheng, G., Song, L. (2006) Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci., 78, 2564-2570.
18. Gasche, Y., Fujimura, M., Morita-Fujimura, Y., Copin, J.C., Kawase, M., Massengale, J., Chan, P.H. (1999) Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab., 19, 1020-1028.
19. Gidday, J.M., Gasche, Y.G., Copin, J.C., Shah, A.R., Perez, R.S., Shapiro, S.D., Chan, P.H., Park, T.S. (2005) Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol., 289, H558-H568.
20. Gómez-Hernández, A., Sánchez-Galán, E., Ortego, M., Martín-Ventura, J.L., Blanco-Colio, L.M., Tarín-Vicente, N., Jiménez-Nacher, J.J., López-Bescos, L., Egido, J., Tuñón, J. (2008) Effect of intensive Atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-STelevation acute coronary syndrome. Am. J. Cardiol., 102, 12-18.
21. Gu, Z., Kaul, M., Yan, B., Kridel, S.L., Cui, J., Strongin, A., Smith, J.W., Liddington, R.C., Lipton, S.A. (2002) S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death. Science, 297, 1186-1190.
22. Guo, R.W., Yang, L.X., Wang, H., Liu, B., Wang, L. (2008) Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB- dependent pathway in vascular smooth muscle cells. Regul. Pept., 147, 37-44.
23. Gurney, K.J., Estrada, E.Y., Rosenberg, G.A. (2006) Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol. Dis., 23, 87-96.
24. Haddad, M., Beray-Berthat, V., Cogueran, B., Palmier, B., Szabo, C., Plotkine, M., Margaill, I. (2008) Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice. Eur. J. Pharmacol., 588, 52-57.
25. Ho, T.Y., Bagnell, C.A. (2004) Relaxin induces matrix metalloproteinase-9 through activation of nuclear factor kappa B in human THP-1 cells. In: Sherwood, O.D. Fields, P.A. Steintz. B.G. Ed, 4th International Conference on Relaxin and Related Peptides. Moran, WY. pp. 314-316.
26. Horstmann, S., Kalb, P., Koziol, J., Gardner, H., Wagner, S. (2003) Profiles of mtrix metalloproteinases, their inhibitors, and laminin in stroke patients- Influence of different therapies. Stroke, 34, 2165-2170.
27. Hosomi, N., Mizushige, K., Kitadai, M., Ohyama, H., Ichihara, S.I., Takahashi, T., Matsuo, H. (1999) Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia. Brain Res., 835, 188-196.
28. Hosomi, N., Nishiyama, A., Ban, C.R., Naya, T., Takahashi, T., Kohno, M., Koziol, J.A. (2005) Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience, 134, 225-231.
29. Jiang, X., Namura, S., Nagata, I. (2001) Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci. Lett., 305, 41-44.
30. Lee, H., Park, J.W., Kim, S.P., Lo, E.H., Lee, S.R. (2009) Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol. Dis., 34, 189-198.
31. Lee, S.R., Kim, H.Y., Rogowska, J., Zhao, B.Q., Bhide, P., Parent, J.M., Lo, E.H. (2006) Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci., 26, 3491-3495.
32. Liebetrau, M., Burggraf, D., Wunderlich, N., Jäger, G., Linz, W., Hamann, G.F. (2005) ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neurosci. Lett., 376, 205-209.
33. Liu, J.F., Crépin, M., Liu, J.M., Barritault, D., Ledoux, D. (2002) FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem. Bioph. Res. Commun., 293, 1174-1182.
34. Liu, R., Wen, Y., Perez, E., Wang, X., Day, A.L., Simpkins, J.W., Yang, S.H. (2005) 17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female. Brain Res., 1060, 55-61.
35. Lo, E.H. (2008) A new penumbra: transitioning from injury into repair after stroke. Nat. Med., 14, 497-500.
36. Ma, Z., Shah, R.C., Chang, M.J., Benveniste, E.N. (2004) Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol. Cell. Biol., 24, 5496-5509.
37. Machado, L.S., Kozak, A., Ergul, A., Hess, D.C., Borlongan, C.V., Fagan, S.C. (2006) Delayed minocycline inhibits ischemia-activated matrix metalloprotein- ases 2 and 9 after experimental stroke. BMC Neurosci., 7, 56.
38. Magnoni, S., Baker, A., Thomson, S., Jordan, G., George, S.J., McColl, B.W., McCulloch, J., Horsburgh, K. (2007) Neuroprotective effect of adenoviral-mediated gene transfer of TIMP-1 and-2 in ischemic brain injury. Gene Ther., 14, 621-625.
39. Manabe, S., Gu, Z., Lipon, S.A. (2005) Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci., 46, 4747-4753.
40. Montaner, J., Alvarez-Sabín, J., Molina, C., Anglés, A., Abilleira, S., Arenillas, J., González, M.A., Monasterio, J. (2001) Matrix metalloproteinase expression after human cardioembolic stroke - Temporal profile and relation to neurological impairment. Stroke, 32, 1759-1766.
41. Montaner, J., Alvarez-Sabín, J., Molina, C.A., Anglés, A., Abilleira, S., Arenillas, J., Monasterio, J. (2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke, 32, 2762-2767.
42. Montaner, J., Molina, C.A., Monasterio, J., Abilleira, S., Arenillas, J.F., Ribó, M., Quintana, M., Alvarez-Sabín, J. (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation, 107, 598-603.
43. Montaner, J., Rovira, A., Molina, C.A., Arenillas, J.F., Ribó, M., Chacón, P., Monasterio, J., Alvarez-Sabín, J. (2003) Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J. Cereb. Blood Flow Metab., 23, 1403-1407.
44. Murono, S., Yoshizaki, T., Sato, H., Takeshita, H., Furukawa, M., Pagano, J.S. (2000) Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res., 60, 2555-2561.
45. Murphy, G., Nagase, H., (2008) Progress in matrix metalloproteinase research. Mol. Aspects Med., 29, 290-308.
46. Nagel, S., Su, Y., Horstmann, S., Heiland, S., Gardner, H., Koziol, J., Martinez-Torres, F.J., Wagner, S. (2008) Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat - Effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res., 1188, 198-206.
47. Ospina, J.A., Brevig, H.N., Krause, D.N., Duckles, S.P. (2004) Estrogen suppresses IL-1 beta-mediated induction of COX-2 pathway in rat cerebral blood vessels. Am. J. Physiol. Heart Circ. Physiol., 286, H2010-H2019.
48. Park, K.P., Rosell, A., Foerch, C., Xing, C., Kim, W.J., Lee, S., Opdenakker, G., Furie, K.L., Lo, E.H. (2009) Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in Rats. Stroke, 40, 2836-2842.
49. Pfefferkorn, T., Rosenberg, G.A. (2003) Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke, 34, 2025-2030.
50. Planas, A.M., Solé, S., Justicia, C. (2001) Expression and activation of matrix metalloproteinase-2 and-9 in rat brain after transient focal cerebral ischemia. Neurobiol. Dis., 8, 834-846.
51. Ruhul Amin, A.R., Senga, T., Oo, M.L., Thant, A.A., Hamaguchi, M. (2003) Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1 beta: a role for the dual signalling pathways, Akt and Erk. Genes Cells., 8, 515-523.
52. Romanic, A.M., White, R.F., Arleth, A.J., Ohlstein, E.H., Barone, F.C. (1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats - Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke, 29, 1020-1030.
53. Rosell, A., Cuadrado, E., Ortega-Aznar, A., Hernández-Guillamon, M., Lo, E.H., Montaner, J. (2008) MMP-9-Positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke, 39, 1121-1126.
54. Rosell, A., Lo, E.H. (2008) Multiphasic roles for matrix metalloproteinases after stroke. Curr. Opin. Pharmacol., 8, 82-89.
55. Rosell, A., Ortega-Aznar, A., Alvarez-Sabín, J., Fernández-Cadenas, I., Ribó, M., Molina, C.A., Lo, E.H., Montaner, J. (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke, 37, 1399-1406.
56. Rosenberg, G.A. (2002) Matrix metalloproteinases in neuroinflammation. Glia, 39, 279-291.
57. Rosenberg, G.A. (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol., 8, 205-216.
58. Rosenberg, G.A., Estrada, E.Y., Dencoff, J.E. (1998) Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 29, 2189-2195.
59. Rush, T.S. 3rd, Powers, R. (2004) The application of X-ray, NMR, and molecular modeling in the design of MMP inhibitors. Curr. Top. Med. Chem., 4, 1311-1327.
60. Solé, S., Petegnief, V., Gorina, R., Chamorro, A., Planas, A.M. (2004) Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J. Neuropathol. Exp. Neurol., 63, 338-349.
61. Sun, J.T., Feng, A., Zhang, Y., Sun, S.Z., Hu, W.X., Yang, M.X., Wei, F.C., Qu, X. (2009) Fucoidan increases TNF-a-induced MMP-9 secretion in monocytic cell line U937. Inflamm. Res., Sep 23, [Epub ahead of print].
62. Suyama, K., Shapiro, I., Guttman, M., Hazan, R.B. (2002) A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell, 2, 301-314.
63. Tanaka, H., Takai, S., Jin, D., Furubayashi, K., Inoue, N., Kajimoto, Y., Miyatake, S., Kuroiwa, T., Miyazaki, M. (2007) Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats. Hypertens. Res., 30, 469-475.
64. Tsubokawa, T., Solaroglu, I., Yatsushige, H., Cahill, J., Yata, K., Zhang, J.H. (2006) Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. Stroke, 37, 1888-1894.
65. Tziakas, D.N., Chalikias, G.K., Parissis, J.T., Hatzinikolaou, E.I., Papadopoulos, E.D., Tripsiannis, G.A., Papadopoulou, E.G., Tentes, I.K., Karas, S.M., Chatseras, D.I. (2004) Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int. J. Cardiol., 94, 269-277.
66. Van den Steen, P.E., Van Aelst, I., Hvidberg, V., Piccard, H., Fiten, P., Jacobsen, C., Moestrup, S.K., Fry, S., Royle, L., Wormald, M.R., Wallis, R., Rudd, P.M., Dwek, R.A., Opdenakker, G. (2006) The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem., 281, 18626-18637.
67. Wang, G.M., Guo, Q.M., Hossain, M., Fazio, V., Zeynalov, E., Janigro, D., Mayberg, M.R., Namura, S. (2009) Bone marrow-derived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Res., 1294, 183-192.
68. Wang, Y., Deng, X.L., Xiao, X.H., Yuan, B.X. (2007) A nonsteroidal anti-inflammatory agent provides significant protection during focal ischemic stroke with decreased expression of matrix metalloproteinases. Curr. Neurovasc. Res., 4, 176-183.
69. Woo, J.H., Lim, J.H., Kim, Y.H., Suh, S.I., Min, D.S., Chang, J.S., Lee, Y.H., Park, J.W., Kwon, T.K. (2004) Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene, 23, 1845-1853.
70. Xu, Z., Zhao, S., Zhou, H., Ye, H., Li, J. (2004) Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin. Chem., 50, 750-753.
71. Zhang, X.J., Wang, Y., Yamamoto, G., Tachikawa, T. (2009) Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. Histopathology, 55, 250-260.
72. Zhao, B.Q., Ikeda, Y., Ihara, H., Urano, T., Fan, W., Mikawa, S., Suzuki, Y., Kondo, K., Sato, K., Nagai, N., Umemura, K. (2004) Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood, 103, 2610-2616.
73. Zhao, B.Q., Tejima, E., Lo, E.H. (2006) Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. 25th Princeton Conference on Cerebrovascular Disease. Portland, OR. pp. 748-752.
74. Zhao, B.Q., Wang, S., Kim, H.Y., Storrie, H., Rosen, B.R., Mooney, D.J., Wang, X.Y., Lo, E.H. (2006) Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med., 12, 441-445.
75. Zhao, X., Benveniste, E.N. (2008) Transcriptional Activation of human matrix metalloproteinase-9 gene expression by multiple Co-activators. J. Mol. Biol., 383, 945-956.
76. Zheng, Y.Q., Liu, J.X., Wang, J.N., Xu, L. (2007) Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. Brain Res., 1138, 86-94.